Axentis Pharma has encapsulated the active compound tobramycin into biologically inactive liposomes, being the carrier of the drug for a prolonged, high local drug concentration.

Axentis Pharma owns world-wide (except Japan and Korea) development and marketing rights to AX-TOBRA™ through an exclusive licensing agreement with aRigen Inc., Japan. Midterm, Axentis Pharma will exploit the Fluidosomes™ technology to target additional chronic lung diseases such as non-CF bronchiectasis.